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Background: Selol is an oily mixture of selenitetriacylglycerides that was obtained as a semi-synthetic compound
containing selenite. Selol is effective against cancerous cells and less toxic to normal cells compared with inorganic
forms of selenite. However, Selol’s hydrophobicity hinders its administration in vivo. Therefore, the present study
aimed to produce a formulation of Selol nanocapsules (SPN) and to test its effectiveness against pulmonary
adenocarcinoma cells (A549).
Results: Nanocapsules were produced through an interfacial nanoprecipitation method. The polymer shell was
composed of poly(methyl vinyl ether-co-maleic anhydride) (PVM/MA) copolymer. The obtained nanocapsules were
monodisperse and stable. Both free Selol (S) and SPN reduced the viability of A549 cells, whereas S induced a
greater reduction in non-tumor cell viability than SPN. The suppressor effect of SPN was primarily associated to the
G2/M arrest of the cell cycle, as was corroborated by the down-regulations of the CCNB1 and CDC25C genes.
Apoptosis and necrosis were induced by Selol in a discrete percentage of A549 cells. SPN also increased the
production of reactive oxygen species, leading to oxidative cellular damage and to the overexpression of the GPX1,
CYP1A1, BAX and BCL2 genes.
Conclusions: This study presents a stable formulation of PVM/MA-shelled Selol nanocapsules and provides the first
demonstration that Selol promotes G2/M arrest in cancerous cells.Background
Low therapeutic efficacy and drug resistance are the most
common problems related to the currently available che-
motherapeutic agents used in tumoral clinical application.
In the search for new chemotherapeutic drugs, several sel-
enium (Se) compounds shown anticancer and anticarcino-
genic activities [1,2]. In particular, those containing Se at
its 4+ oxidation state, namely selenite, present the highest
antioxidant and anticancer activities [2]. However, Se(IV)-
containing compounds generally present high systemic
toxicity, limiting their clinical application. In this context,
a selenite-containing compound named Selol, which was
first obtained at Warsaw Medical University, Poland [3],
has shown antitumor activity and low systemic toxicity
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unless otherwise stated.and appears to act primarily through the induction of oxi-
dative stress in cancer cells [5]. Interestingly, Selol was
shown to sensitize leukemia cells to the cytotoxicity of
vincristine and doxorubicin, insomuch that it was sug-
gested that Selol could be used in combination with other
drugs in chemotherapeutic protocols [4].
The potential synergism of Selol with classical antican-
cer drugs can be exploited to treat tumors, such as non-
small cell lung cancer (NSCLC) [4]. NSCLC, whose most
frequently observed histological subtype is adenocarcin-
oma, is particularly aggressive and the leading cause of
cancer death worldwide [6,7]. It is estimated that more
than 75% of patients with NSCLC present locally ad-
vanced or metastatic disease, severely limiting the success
of treatments [8,9]. Platinum-based treatment, which is
the most recommended first-line therapy, reaches re-
sponse rates of only 20-40% and mean survivals between 7
and 12 months [8,10,11]. Multidrug protocols and a treat-
ment break with non-platinum-based drugs after a fixedal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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long the survival of NSCLC patients [12,13]. Thus, Selol
may be a potential candidate for combined anti-NSCLC
strategies [14].
Despite the therapeutic potential presented by Selol,
its hydrophobicity is a major obstacle to its biological
application. For instance, high hydrophobicity often hin-
ders intravenous (iv) administration and may thus confer
an undesirable pharmacokinetic profile [15]. This prob-
lem can be circumvented through the nanoencapsulation
of Selol in an aqueous vehicle to form a nanocapsule-
based drug delivery system. The nanoencapsulation of
Selol with a polymer presenting highly reactive chemical
groups allowing surface modification could bring up
new possibilities for delivering this anticancer agent. In
this context, the copolymer poly(methyl vinyl ether-co-
maleic anhydride) (PVM/MA) has been reported to be
a biocompatible and biodegradable material useful for
preparing drug delivery systems [16]. Additionally, the
copolymer PVM/MA presents a surfactant effect and
anhydride groups, which readily react with a series of
molecules. On that ground, we report the development
and the first in vitro efficacy tests of a PVM/MA-shelled
Selol nanocapsule formulation intended for the treat-
ment of lung adenocarcinomas.
Results and discussion
Formulation screening
The interfacial precipitation method of preformed poly-
mer through solvent displacement yields nanosized
Selol capsules only within a certain range of solute and
solvent concentrations. Thus, to identify the best for-
mulation parameters, different concentrations of each
component were tested.
First, different Selol-to-PVM/MA ratios were tested
(0.1, 0.2, 0.5, 0.7, 1.0, 1.5, 2.0, and 4.0, w:w), and the con-
centrations of acetone, ethanol and water were fixed to
20, 40 and 40% (v:v), respectively. As shown in Figure 1
(a), the increase in this ratio led to a directly propor-
tional increase in the hydrodynamic diameter (HD)
values of the nanocapsules. Using Selol-to-PVM/MA ra-
tios from 0.1 to 1.0, monodisperse nanocapsule popula-
tions were obtained, and the polydispersity index (PDI)
values remained below 0.1. Formulations prepared with
Selol-to-PVM/MA ratios higher than 1.0 showed visible
decantation minutes after preparation and were not
used for dynamic light scattering analysis. Therefore,
this parameter was set to 1.0 for the next steps because
this was the highest value that allowed stable nanocap-
sules to be obtained.
Next, different concentrations of Selol plus PVM/MA
were tested. The concentrations of acetone, ethanol and
water were set to 20, 40 and 40% (v:v), respectively. As
expected, smaller nanocapsules were obtained at thelowest concentrations of Selol plus PVM/MA (Figure 1
(b)). The PDI was not significantly affected by this vari-
able, remaining close to 0.1. The concentration of Selol
plus PVM/MA was set to 0.8% (w:v) in further experi-
ments because it provided good colloidal characteristics
in addition to a good yield of nanocapsules.
Then, different concentrations of acetone and ethanol
were tested in the process of encapsulation with 0.8%
Selol plus PVM/MA and a ratio of 1.0 Selol-to-PVM/
MA. Different volumes of acetone were used for dissolv-
ing a fixed amount of Selol and PVM/MA, and the final
volume reached 100% with ethanol:water (1:1, v:v). As
shown in Figure 1(c), a major change in the nanocapsule
HD was observed with 40% acetone, but the PDI
remained below 0.1. When the concentration of acetone
was set to 20% and varying volumes of ethanol were
added, it was observed that the HD of the nanocapsules
decreased with higher concentrations of ethanol (Figure 1
(d)). The highest HD and PDI values were obtained with
20% ethanol.
Given the results described above, the protocol of Selol
nanoencapsulation was established as follows: 1) 100 mg
of PVM/MA and 100 mg of Selol were dissolved in 5 mL
of acetone; 2) 10 mL of ethanol and 10 mL of water were
added; and 3) the purification steps were then performed.
The method of nanoprecipitation by solvent displace-
ment yielded monodisperse nanocapsules at almost all of
the conditions tested and also allowed modulation of the
nanocapsule diameter. Noteworthy, by varying the con-
centrations of acetone and ethanol, nanocapsules of dif-
ferent HDs were obtained, likely due to differences in
solvent diffusion, as previously suggested [17]. Even for a
concentration of nanocapsule components (Selol plus
PVM/MA) near the upper critical limit of 2%, as noted
by Aubry et al. (2009) [18] for this method, stable and
monodisperse nanocapsules were obtained. As expected,
at higher concentrations of Selol, larger capsules were
obtained, which can be attributed to the nucleation-and-
growth phenomenon [19,20].
Characterization of Selol nanocapsules
The Selol nanocapsules (SPN) formulation presented a
single population of nanocapsules with an HD of 344.4 ±
4.8 nm, a PDI of 0.061 ± 0.005 and a zeta potential (ζ po ten-
tial) of −29.3 mV± 1.5. The transmission electron micro-
scope (TEM) image revealed a population of nanocapsules
with an average diameter of 207.9 ± 80.9 nm (Figure 1(e)).
These nanometric structures presented a spherical shape
and slightly rough surface, as observed with a scanning
electron microscope (SEM) (Figure 1(f)). A spherical equi-
librium shape is expected with this method due to the
three-dimensional primordial droplet nuclei growth con-
ferred by the interfacial tension between the droplets and
the dispersant [20,21]. Furthermore, according to the
Figure 1 Characterization of Selol nancapsules. Values of the hydrodynamic diameters (HD) (in squares) and polydispersity indexes (PDI) (in
diamond) of PVM/MA-shelled Selol nanocapsules as a function of the Selol-to-PVM/MA ratio (a), concentration of Selol plus PVM/MA (b), acetone
(c), and ethanol (d). Morphology of Selol-PVM/MA nanocapsules (SPN) observed by TEM (e) and SEM (f). Magnification: 25.000 × .
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formable. Both the deformability and the spherical
shape of the nanocapsules are interesting for their ad-
ministration through parenteral routes [22].
The dosage of the purified Selol nanocapsules showed
that the concentration of Selol measured in the nano-
capsule was approximately 100% of the initial amount of
Selol used in the process. Supported by the low PDI of
the Selol composition, this result confirms that Selol was
efficiently encapsulated into the PVM/MA shell. How-
ever, it was necessary to evaluate the copolymer’s cap-
acity for interfacial stabilization after prolonged periods
of storage and thermal stress conditions. As observed in
Table 1, the SPN was stable at room temperature (RT)
for at least 60 days. Under these conditions, there was
no statistically significant change in the HD over the
evaluated period of time. When stored at 4°C, the SPN
average HD increased by approximately 40 nm on thefirst day and then remained stable. At both RT and 4°C,
the PDI remained well below 0.1, showing that the nano-
capsules remained monodisperse. At −20°C, significant
variations were observed in both the HD and PDI (>0.3),
indicating that this condition is not adequate for storage.
After freezing/thawing cycles, no significant changes in
both the HD and PDI (p > 0.05) were found up to the
eighth cycle. Indeed, PVM/MA presented good capacity
for interfacial stabilization in SPN because this system
did not present any important changes in its characteris-
tics, neither after 60 days of storage (at RT or 4°C) nor
after being subjected to the thermal stress of eight cycles
of freezing/thawing. The ζ potential of the nanocapsules
was generally between −25 and −30 mV at all of the con-
ditions tested, which is due to the presence of carboxyl-
ate groups on their outer surface. A hypothetical scheme
of the PVM/MA-shelled Selol nanocapsules is shown in
Figure 2. Over the course of encapsulation, the PVM/
Table 1 Thermodynamic stability and dispersibility studies of Selol-PVM/MA nanocapsules
Formulation Hydrodynamic diameter ± S.D. (nm) Polydispersity index Zeta potential (mV)
Room temperature
Day 0 344.4 ± 4.8a 0.061 −29.3
Day 15 349.7 ± 8.2a 0.049 −29.7
Day 30 338.9 ± 6.4a 0.046 −29.2
Day 45 344.3 ± 2.0a 0.034 −26.5
Day 60 336.6 ± 4.6a 0.043 −29.4
4°C
Day 0 344.4 ± 4.8a 0.061 −29.3
Day 1 390.2 ± 1.0b 0.054 −29.3
Day 15 391.3 ± 7.5b 0.044 −25.1
Day 30 373.9 ± 15.0b 0.046 −27.8
Day 45 381.6 ± 8.9b 0.031 −30.1
Day 60 380.6 ± 7.1b 0.039 −27.3
−20°C
Day 0 344.4 ± 4.8a 0.061 −29.3
Day 1 414.2 ± 7.7c 0.074 −29.2
Day 15 408.2 ± 10.7c 0.113 −27.0
Day 30 471.0 ± 1.3d 0.195 −27.4
Day 45 615.2 ± 13.3e 0.278 −29.8
Day 60 566.3 ± 14.8f 0.196 −26.5
Freezing (−20°C) and thawing cycle
No cycle 344.4 ± 4.8 0.061 −29.3
I 414.2 ± 7.74 0.074 −29.2
II 414.1 ± 10.0 0.066 −28.9
III 406.7 ± 4.5 0.035 −28.9
IV 410.2 ± 4.7 0.045 −28.1
V 416.5 ± 4.3 0.064 −22.9
VI 405.5 ± 6.0 0.046 −28.5
VII 425.8 ± 0.9 0.079 −28.8
VIII 467.3 ± 9.9 0.143 −27.0
IX 486.5 ± 17.1* 0.106 −28.8
X 495.1 ± 1.0* 0.177 −30.8
XI 509.3 ± 6.6* 0.221 −28.9
XII 566.2 ± 3.5* 0.364 −28.7
XIII 865.1 ± 50.4* 0.581 −27.7
XIV 989.1 ± 26.6* 0.433 −26.9
XV 1027.5 ± 60.7* 0.393 −28.8
All values were expressed as the means ± standard error of the mean. Different letters indicate significant differences between SPN treatment for one day at RT
compared with a given time and/or storage condition (p < 0.05). *Significantly different compared with the first cycle of freezing (−20°C) and thawing (p < 0.05).
de Souza et al. Journal of Nanobiotechnology 2014, 12:32 Page 4 of 17
http://www.jnanobiotechnology.com/content/12/1/32MA copolymer, which is poorly soluble in water, be-
comes amphipathic due to the hydrolysis of some of its
anhydride groups exposed to water. The formed polymer
shell presents a hydrophilic water-exposed surface, facili-
tating the stabilization of nanocapsules.Selol nanocapsules affect cell viability in a concentration-
and time-dependent manner
The MTT assay showed that nanoparticles of PVM/MA
without Selol (Bl) did not significantly affect the viability
of the studied cells (Figure 3). Significant reductions in
Figure 2 Schematic representation of PVM/MA-shelled Selol nanocapsules. Hydrolysis of an anhydride group yields two carboxylate groups
at neutral pH in a PVM/MA strand (a). Partial hydrolysis of the PVM/MA polymer strand exposed to water but not in PVM/MA closer to the oily core
(b). The carboxylate-containing parts of PVM/MA are hydrophilic and comprise the nanocapsule shell surface, whereas the anhydride-containing parts
are more hydrophobic, closely covering the Selol core (c).
Figure 3 Viability of A549 (a, b, e) and human connective tissue (c, d, f) cells after exposure to Selol-PVM/MA nanocapsules (SPN)
(a, c), free Selol (S) (b, d), blank polymeric nanoparticles without Selol (Bl) (a, c) or sodium selenite (SS) (e, f) at 50, 100 and 150 μg/mL
Se for 24 h, 48 h and 72 h. All of the values were normalized according to the control group at 24 h (100%). The time-dependent proliferation
of control cells was significantly different. *Statistically significant compared with the control group at the corresponding treatment period
(p < 0.05). Influence of SPN at a concentration of 100 μg Se/mL on the proliferation of A549 (g) and human connective tissue (h) cells evaluated
after different treatment times. Pairs of means in a same graph identified with different letters are significantly different (p < 0.05).
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Figure 4 Viability of A549 and human connective tissue cells
treated with Selol-PVM/MA nanocapsules (SPN) after 1 and
60 days of storage at 4°C. The cells were treated with 50, 100 and
150 μg/mL Se for 72 h, and the data are expressed as the means ±
standard error of the mean of the percentages of viable cells. No
statistically significant difference was found between the results for
SPN after 1 day and SPN for 60 days (p > 0.05).
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were observed after exposure to SPN or free Selol (S) at
concentrations of 50 μg/mL for 72 h and 100 and
150 μg/mL for 48 and 72 h (p < 0.05). In contrast, tissue
connective normal cells were shown to be less sensitive
to Selol compared with tumor cells. Free Selol treatment
reduced the viability of normal cells after 48 h, whereas
SPN reduced their viability only after 72 h of incubation.
Sodium selenite (SS) was highly toxic for both cell types
at all concentrations and times tested. The high toxicity
of SS toward normal cells shows that selenite is an ef-
fective anticancer agent but is not safe for clinical use in
its inorganic form. Therefore, some researchers have
aimed to find organic selenium compounds with higher
therapeutic indexes [23,24]. Selol, an organic selenite
compound, significantly reduced the viability of lung
adenocarcinoma A549 cells but was far less toxic on
normal cells than sodium selenite. This finding rein-
forces the previously shown evidence that Se (4+) orga-
nified as Selol has a significantly lower potential to exert
deleterious effects on non-target tissues than its inor-
ganic form [4,25,15]. Noteworthy, the encapsulation of
Selol did not significantly affect its activity against A549
cells and reduced its toxicity toward normal cells. These
results encourage further tests of Selol activity in in vivo
models of pulmonary cancer. Moreover, some character-
istics of the investigated nanocapsules point to their po-
tential to act as good drug delivery systems. First, their
hydrodynamic diameters can be tuned to values that
allow for the passive targeting of tumors via an en-
hanced permeation and retention effect (EPR) because
the tumor microvasculature usually presents pores with
diameters of 100 to 780 nm [26]. Second, targeting mol-
ecules can be conjugated to the surface of nanocapsules
to increase their affinity to cancerous cells. This proced-
ure can be easily performed because PVM/MA has an-
hydride groups, which can easily react with the hydroxyl
or primary amine groups present in most of the available
targeting molecules [16].
Subsequent experiments with SS, S and SPN were
performed with a concentration of 100 μg/mL Se be-
cause this was the lowest concentration in S and SPN
treatments that reduced cell viability. Moreover, SPN
was always used within 60 days after preparation be-
cause its biological activity did not significantly change
during storage at 4°C for this period of time (p > 0.05)
(Figure 4).
SPN reduces cell proliferation and promotes cell cycle arrest
As expected, both untreated normal and A549 cells pro-
liferate in culture, as evidenced by the time-dependent
increase in the number of cells (p < 0.001 for both 24 vs.
48 h and 48 vs. 72 h for A549; p < 0.01 for 24 vs. 48 h,
and p < 0.05 for 48 vs. 72 h for normal cells) (Figure 3(g and h)). SPN treatment inhibited the proliferation of
both cell types, but the intensity of this effect was cell
line-dependent. The number of both normal and tumor
cells in the SPN-treated groups did not vary over the
treatment time (p > 0.05). Reductions of 40.4 ± 2.7% and
64.7 ± 1.7% in the number of SPN-treated A549 cells
were evidenced at 48 h (p < 0.001) and 72 h (p < 0.001),
respectively, relative to the control A549 cells. However,
normal cells were affected to a lesser extent because a
significant reduction in their number was observed only
at 72 h (24.8 ± 6.7%, p < 0.01) compared with the control
normal cells.
The real-time cell index monitoring also showed
changes in this parameter after the first hours of SPN
treatment on A549 cells, which became more significant
for higher concentrations and longer times of incubation
(Figure 5). Cell growth was detected up to 20 h, 28 h and
56 h in the presence of SPN at 150 μg/mL, 100 μg/mL
and 50 μg/mL concentrations, respectively. Over these
times, the cell indexes remained constant and subse-
quently decreased. Similar to previous results, the cell
index in the treatment with 100 μg/mL SPN was almost
invariant at 24, 48, and 72 h.
These results were corroborated by light microscopy
images, which showed a more intense reduction in the
confluence of SPN-treated A549 cells compared with
SPN-treated normal cells (Figure 6). A549 cells treated
with SPN presented a significantly higher proportion of
cells arrested at the G2/M phase compared with that ob-
tained for control cells (Table 2). These results are in
good agreement with the decreases in the gene expres-
sion levels of CCNB1 (cyclin B1), CDC25C and WEE1
(FC (fold change) > 2.0) and unchanged expression levels
of the gene transcripts of CCND1 (cyclin D1) and
CCNE1 (cyclin E1) (FC < 2.0) (Figure 7(a)), indicating
that Selol acts on the G2/M arrest of the cell cycle and
Figure 5 Real-time monitoring of cell indexes of A549 cells untreated (control) and treated with Selol-PVM/MA nanocapsules (SPN)
at Se concentrations of 50, 100 and 150 μg/mL for 100 h. All of the treatments started 24 h after cell plating, as indicated by the vertical grey
continuous line on the top panel. The bottom panel shows more detailed dynamic monitoring in the range of 15 h to 47 h after the treatment,
and the time intervals with constant cell indexes are indicated on the bottom panel (values should be related to the treatment and not to the
time after cell plating).
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to SPN treatment, the expression levels of CCNB1 and
CDC25C were reduced by half at 24 h and were mark-
edly down-regulated after 48 h (approximately 17-fold
for CCNB1 and 21-fold for CDC25C) and 72 h (approxi-
mately 25-fold for CCNB1 and 50-fold for CDC25C)
compared with the control cells. The expression of
WEE1 was reduced only to half at 48 h and 72 h.
In relation to normal cells, A549 cells were more sus-
ceptible to Selol, both free and encapsulated, which
may be partially due to enhanced endocytic activity
[27]. Another possible explanation that is supported by
the results of the present study is that tumor cells may
be more sensitive to Selol due to their higher prolifera-
tion rates because Selol appears to primarily act as an
inhibitor of cell proliferation. SPN significantly in-
creased the percentage of A549 cells arrested in the
G2/M phase of cell cycle and consequently reduced the
number of living cells. In the G2 phase, the wee1 pro-
tein inactivates the mitosis promoting factor (cyclin
B1/CDK1), and cdc25C is a positive regulator of this
complex. As shown in previous studies, G2/M arrest
may require activation of wee1 in addition to inactiva-
tion of cdc25C [28,29].Additionally, the decrease in cell proliferation induced
by Selol was not associated with a decreased energy me-
tabolism coordinated by the main mitochondrial deacety-
lase sirtuin 3 [30], as observed by the unchanged
transcript levels of the SIRT3 gene (FC < 2.0) (Figure 7(a)).
Moreover, subtle changes in the expression of the β-actin
gene (ACTB) in SPN-treated cells compared with un-
treated cells showed that this gene is not suitable as an en-
dogenous control for SPN treatment (Figure 7(a)), likely
due to association of the β-actin protein with cytoskeletal
components and consequent cell division events [31].
Morphological alterations
Phase contrast microscopy revealed that neither SPN
nor free Selol induced morphological changes in A549
cells. SPN treatment did not induce any morphological
alterations in normal cells because most of them were
shown to be spindle-shaped with cytoplasmic projec-
tions, as expected. In contrast, free Selol induced visible
cytoplasmic retraction (arrows) in normal cells (Figure 6).
Comparatively, pronounced morphological changes were
induced by SS in both normal and A549 cells.
Some ultrastructural signs of cell death were observed
in A549 cells after treatment with Selol. Mitochondrial
Figure 6 Morphology of human cells from connective tissue (a, b, c, d) and A549 cells (e, f, g, h). The cells were untreated (a, e), exposed
to free Selol (S) (b, f) or to Selol-PVM/MA nanocapsules (SPN) (c, g) for 72 h. Morphologic changes due to sodium selenite (SS) treatment for
24 h (d, h). Decrease in cell confluence by S and SPN treatments. Normal morphology of A549 (f, g) and SPN-treated connective tissue cells.
Cytoplasmic retraction (arrows) on human cells from connective tissue after treatment with S (b). The bright, black-bordered spherical structures
are free Selol microdroplets (b, f). Magnification: 20x.
Table 2 Effect of Selol-PVM/MA nanocapsule (SPN) treatment
on the cell cycle distribution of A549 cells
A549 G0/G1 (%) S (%) G2/M (%)
Control 48 h 69.6 ± 2.9 18.4 ± 2.3 12.2 ± 1.3
SPN 48 h 56.6 ± 3.8 26.5 ± 0.9 16.9 ± 3.7*
Control 72 h 70.7 ± 3.9 18.8 ± 2.9 10.6 ± 1.7
SPN 72 h 56.2 ± 1.3 25.0 ± 1.9 18.7 ± 2.7*
*p < 0.05 compared with the control. The data were obtained from three
independent experiments and are presented as the means ± standard error of
the mean.
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Additionally, cytoplasm swelling suggestive of necrosis was
present. These morphological changes suggest that apop-
tosis and necrosis are induced by treatment with Selol.
Most of the normal cells did not present any morpho-
logical changes after SPN treatment (Figure 9). However,
the cells exposed to free Selol presented large endosomes
containing Selol, whereas the SPN-treated cells did not
present visible Selol particles. Endocytosis of free Selol
droplets in both cell lines caused the compression of adja-
cent organelles. In addition, an unambiguous identification
of Selol nanoparticles was not possible due to similarities
with cellular lipids.
Figure 7 Relative gene expression of A549 cells treated with Selol-PVM/MA nanocapsules (SPN) at a concentration of 100 μg/mL for
24 h, 48 h and 72 h (a). The following genes were down-regulated: CCNB1, CDC25C and WEE1. The following genes were up-regulated: BCL2,
BAX, GPX1 and CYP1A1. *FC > 2.0. Production of reactive oxygen species (ROS) in A549 (b) and HL60 (c) cells treated with SPN at a concentration
of 100 μg/mL (SPN). SPN-treated samples were normalized according to the control samples (Ctl). The bars represent the means ± standard error.
*p < 0.001.
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S and SPN induced the exposure of phosphatidylserine on
the outer leaflet of the plasma membrane and impairment
of plasma membrane permeability only in a discrete percent-
age of A549 cells. After 72 h of exposure, only 11.2 ± 0.6%
(p < 0.01) and 12.9 ± 2.3% (p < 0.001) of A549 cells were pro-
pidium iodide (PI)- and/or annexin V-positives after S and
SPN treatments, respectively. In control A549 cells, this per-
centage was 2.9 ± 0.5% (Figure 10).
SPN treatment caused an increase in the percentage of
A549 cells presenting reduced mitochondrial membrane
potential (ΔΨm) compared with control cells at 48 h
(14.5 ± 4.2%, p < 0.05) and 72 h (22.8 ± 5.4%, p < 0.001)
(Figure 11(a)). Figure 11(b) also shows the ΔΨm of con-
trol and SPN-treated A549 cells at 72 h. These findings
are compatible with the mitochondrial damages evi-
denced by ultrastructure analysis.
DNA fragmentation increased after 48 h (19.8 ± 1.1%
vs. 3.6 ± 1.0% for control, p < 0.001) and 72 h (24.0 ± 2.5%
vs. 4.6 ± 1.0% for control, p < 0.001) of SPN treatment
(Figure 11(c)). As shown in Figure 11c, this treatment resulted
in an increase in the sub-G1 cell population, a clear reduc-
tion in the percentage of cells in the G1 phase and an increase
in the percentage of cells in the G2/M phase (Figure 11(d)).The levels of transcripts related to apoptosis, namely
BAX (BCL2-associated X protein) and BCL-2 (B-cell
lymphoma 2), increased after 48 h (2-fold and 3-fold for
BAX and BCL-2, respectively) and 72 h (2-fold for both
BAX and BCL-2) (Figure 7(a)). These results suggest
that Selol triggers damages that are able to activate the
apoptosis mechanisms. However, the BAX/BCL2 ratio,
which is recognized as an initiator of the caspases activa-
tion pathway, was slightly increased only at 72 h. The
results presented suggest that the mechanism of action
of Selol in A549 cells is not crucially dependent on the
direct induction of apoptosis or necrosis. Suchocki et al.
(2007) [4] demonstrated mitochondrial changes and DNA
fragmentation in a leukemia cell line, and Estevanato et al.
(2012) [32] and Wilczynska et al. (2011) [25] observed
the translocation of phosphatidylserine in breast and
cervix cancer cell lines. In the present study, the expos-
ition of phosphatidylserine, changes in the mitochon-
drial membrane potential, DNA fragmentation, and/or
alterations in the plasma membrane permeability were
observed in low percentages of A549 cells after treatment
with free or encapsulated Selol. These findings, however,
do not exclude the possibility that Selol may induce exten-
sive A549 cell death at the highest concentrations and/or
Figure 8 Ultrastructural morphology of A549 cells: control (a, b), treated with free Selol (S) (c, d) and treated with Selol-PVM/MA
nanocapsules (SPN) (e, f). Note the integrity of the mitochondria (M), endoplasmic reticulum (ER), plasma membrane (PM), nucleus (N), nuclear
envelope (NE), and cytosol of the control cells. An endocytosed Selol droplet is shown with an arrow in c. Endosomes, as indicated by an
arrow in d, were usually identified with the free Selol treatment. Cytoplasm characteristic of necrotic cells can be observed in e (arrow). Intense
formation of vacuoles (V) containing cellular organelles and changes in the morphology of mitochondria (arrowhead) can be evidenced in
d and f.
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rest may elicit apoptosis insomuch that cell death may not
only be due to primary damage but also result from accu-
mulation of damages arising from the cell cycle arrest
itself [33].
Oxidative stress in A549 cells
The production of reactive oxygen species (ROS) was
evaluated in A549 cells compared with HL60 promyelo-
cytic cells. The HL60 cell line is a cell model that isfrequently used to access the oxidant or antioxidant po-
tential of different compounds [34,35]. In the current
study, Selol surprisingly did not induce an oxidative
burst on HL60 cells (Figure 7(b)). Otherwise, ROS accu-
mulation was observed in A549 cells at higher SPN ex-
posure times (24, 48 and 72 h) (Figure 7(b)). These
findings suggest that the SPN-induced oxidative burst is
variable according to the cell type.
Additionally, increased expression of GPX1 (glutathione
peroxidase 1) (5-fold and 7-fold at 48 h and 72 h,
Figure 9 Ultrastructural morphology of human connective tissue cells: control (a, b), treated with free Selol (S) (c, d) or treated with
Selol-PVM/MA nanocapsules (SPN) (e, f). Note the integrity of the control cells, as expected. In c, a Selol vesicle being taken up by a
cell exposed to free Selol is shown by an arrow. In d, the arrow points to an endosome. In e and f, the ultrastructural morphology is
unchanged by SPN treatment. N, M, ER, GC, PM, and V: nucleus, mitochondria, endoplasmic reticulum, Golgi complex, plasma membrane
and vesicle, respectively.
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Increased levels of ROS coincident with the up-
regulation of GPX1 indicate that A549 cells responded in
response to exposure to SPN by activation of the
antioxidant defense systems. Suchocki et al. (2010)
[5] showed the involvement of ROS and the inhib-
ition of CYP1A1 (cytochrome P450) induced by Selol
in cervix cancer cell lines. Conversely, in this study,
the expression of CYP1A1 (4-fold on both 48 h and
72 h) on A549 cells was enhanced by SPN treatment
(Figure 7(a)). The metabolism and detoxification ofxenobiotics performed by cytochrome P450 may be
associated with SPN metabolism and ROS generation
[36]. Therefore, the present study suggests that ROS
production on A549 cells may be associated with cell
death and inhibition of proliferation, as evidenced by
Chen et al. (2013) [37].
Despite the induction of oxidative stress observed on
A549 cells, SPN had no effect on the gene expression
of catalase at the concentration and times evaluated
(Figure 7(b)), corroborating the results of a study on pros-
tate cancer cells treated with Selol for 24 and 48 h [38].
Figure 10 Influence of free Selol (S) or Selol-PVM/MA nanocapsules (SPN) on A549 cells. Flow cytometry study of cells stained with
propidium iodide (PI) and/or annexin V-FITC. The positive cells are shown as percentages in each quadrant: PI+ (Q1), Annexin V+ (Q3),
double-negative PI− Annexin V− (Q4), and double-positive cells PI+ Annexin V+ (Q2). Negative control (a). Annexin V+ control (b). PI+ control
(c). Untreated cells (d). Similar membrane integrity was observed after S (e) and SPN (f) treatments.
Figure 11 Mitochondrial membrane potential and by DNA fragmentation of A549 cells treated with selol-PVM/MA nanocapsules (SPN)
and untreated cell (control cells, Ctl) at different times. *p < 0.05 for Ctl 48 h vs. SPN 48 h; p < 0.001 for Ctl 72 h vs. SPN 72 h (a). Representative
histogram showing a sample of control cells (red line) and a sample of SPN-treated cells (blue line) after 72 h (b). DNA fragmentation in SPN-treated or
untreated A549 cells at different times. *p < 0.001 for Ctl 48 h vs. SPN 48 h; p < 0.001 for Ctl 72 h vs. SPN 72 h (c). Representative histogram showing
sub-G1 (DNA fragmented), G1, S and G2/M populations for Ctl (red line) and SPN-treated cells (blue line) after 72 h (d).
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This study demonstrates that Selol can act as a cytostatic
agent and corroborates previous reports indicating that
it is effective against cancerous cells and safer for clinical
applications than sodium selenite. Furthermore, the
present study includes the development of a stable and
monodisperse aqueous vehicle for Selol delivery, namely
PVM/MA-shelled Selol nanocapsules, which are able to
maintain the activity of free Selol against pulmonary
adenocarcinoma cells, exhibit reduced toxicity to non-
tumor cells in vitro and are thus potentially suitable for
the treatment of some types of lung cancer. Further
in vivo studies should be performed to evaluate the po-
tential of this formulation for human therapy.
Methods
Materials
Selol composed of 5% selenium (w:w) was provided by
Warsaw Medical University (Poland). PVM/MA (Gantrez
AN 119) was kindly gifted by ISP Corp. (Brazil). Human
lung adenocarcinoma (A549) and promyelocytic leukemia
(HL60) cell lines were purchased from American Type
Culture Collection (USA). Sodium selenite, trifluoroacetic
acid, dimethyl sulfoxide and rhodamine 123 were pur-
chased from Sigma (USA). Dulbecco’s modified Eagle’s
medium, F12 medium, Roswell Park Memorial Institute
medium, 3,4,5-dimethylthiazol-2,5 biphenyl tetrazolium
bromide (MTT), annexin V-FITC and propidium iodide
(PI) were provided by Invitrogen (USA). Fetal bovine
serum, penicillin and streptomycin were purchased from
Gibco (USA). RNase A was obtained from Promega (USA).
Primers and 2’,7’-dichlorodihydrofluorescein diacetate
(DCFH-DA) were acquired from Life Technology (USA).
Phorbol 12-myristate 13-acetate (PMA) was obtained from
Abcam (England). GeneJet RNA purification and cDNA
Maxima kits were provided by Life Science (USA). DNase
I, free-RNase kit was purchased from Thermo Scientific
(USA). The TaqMan gene expression assay was obtained
from AB Applied Biosystems (USA). Grids and supports of
copper and osmium tetroxide were obtained from Electron
Microscopy Sciences (USA). Dichloromethane was pur-
chased from Vetec (Brazil). Ethanol and acetone were pur-
chased from J. T. Baker (USA). Phosphate buffer saline was
obtained from Laborclin (Brazil).
Preparation of nanocapsules
Nanocapsules were prepared through an interfacial nano-
precipitation method. Briefly, Selol (oil phase) and PVM/
MA (surfactant) were dissolved in acetone at room
temperature (RT). Next, ethanol and distilled water were
sequentially added to the acetone solution, under mild stir-
ring, to form a yellowish, opaque suspension. The organic
solvents were removed by distillation at 45°C under reduced
pressure (80 mbar) in a rotavapor apparatus (RotavaporRII®, Buchi Switzerland). Next, the resulting oily nanocap-
sules were centrifuged at 22,000 × g for 30 min, the trans-
parent aqueous supernatant was removed, and the pellet
was resuspended in distilled water. This preparation was
immediately characterized and/or stored at 4°C until usage.
Colloidal characterization
The nanocapsules were dispersed in phosphate buffer
saline (PBS) (pH 7.4) at a concentration of Selol equivalent
to 100 μg/mL. Then, the hydrodynamic diameter (HD)
and polydispersity index (PDI) and the zeta potential
(ζ potential) were measured at 25°C by dynamic light scat-
tering (DLS) and electrophoretic laser Doppler anemometry
(ZetaSizer Nano ZS®, Malvern Instruments), respectively.
Surface morphology and structure
The shape and surface morphology of the capsules were
investigated using a field emission scanning electron
microscope (SEM) (JEOL JSM 7001-F®, Japan). Before
analysis, the composition was diluted with ultrapure water
to 5% (v:v), and 20 μL was deposited onto copper sup-
ports. Next, the sample was fixed with 1% osmium tetrox-
ide vapor (w:v) for 1 h, left to dry at RT and coated with
gold using a Blazers SCD 050® sputter coater (Blazers
Union AG, Liechtenstein). The images were digitized
using an UltraScan® camera connected to the Digital
Micrograph® 3.6.5 computer software (Gatan, USA).
The diameter values of 300 nanocapsules were mea-
sured with the Image Pro-Plus® 5.1 software from images
captured with a transmission electron microscope
(TEM) (JEOL JEM 1011®, Japan). Before this analysis,
the sample was diluted with ultrapure water to 3% (v:v)
and deposited onto a copper grid. The dried sample was
fixed and contrasted with 1% osmium tetroxide vapor
(w:v) for 20 min. The images were digitized using an
UltraScan® camera connected to the Digital Micrograph
3.6.5® computer software (Gatan, USA).
Efficiency of Selol encapsulation
The Selol concentration in the nanocapsules was esti-
mated according to Suchocki et al. (2003) [39]. Briefly,
300 μL of the nanocapsules dispersion was centrifuged
at 22,000 × g and 4°C for 30 min. The pellet was left to
dry at RT for two days. Next, Selol was extracted from
the pellet with 800 μL of dichloromethane and oxidized
with 200 μL of trifluoroacetic acid. The selenium absorb-
ance was measured at a wavelength of 380 nm in a
quartz cuvette. The efficiency of Selol encapsulation was
calculated considering the ratio of the encapsulated mass
to the mass of Selol that was initially used.
Thermodynamic stability studies
Storage at room temperature, 4°C and −20°C. Aliquots of
the nanocapsule dispersion were stored at RT, 4°C or −20°C,
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were evaluated every 15 days.
Freezing and thawing cycles. Fifteen cycles of freezing
(−20°C) and thawing (25°C) were applied to a nanocapsule
aliquot. After each cycle, the HD, PDI and ζ potential were
evaluated.
Cell culture
The A549 human lung adenocarcinoma cell line was cul-
tured with a 1:1 (v:v) mixture of Dulbecco’s modified Eagle’s
medium (DMEM) and F12 medium supplemented with
10% (v:v) fetal bovine serum (FBS) and 1% (v:v) antibiotic
solution (100 units/mL penicillin and 100 mg/mL strepto-
mycin). Human connective tissue cells harvested from the
dental pulp of normal teeth were maintained in primary
culture and used as non-tumor control cells, namely nor-
mal cells [40]. These cells were grown in DMEM supple-
mented with 10% FBS and 1% antibiotic solution, as
described above. Both cells were maintained at 37°C in a
5% CO2 and 80% humidity environment.
Treatment design
The cells were allowed to adhere to culture microplates
for 24 h and were then treated as follows: (1) Selol-
PVM/MA nanocapsules (SPN), (2) free Selol (S), (3)
blank polymeric nanoparticles without Selol (Bl), and
(4) sodium selenite (SS). Cells treated with culture
medium, culture medium/acetone and culture medium/
PBS corresponded to the control groups of SPN, S and
SS, respectively. For the free Selol treatments, Selol was
dissolved in acetone and then added to the culture
medium, as described by Suchocki et al. (2007) [4]. Be-
fore the tests, a viability study was performed to ensure
that the volumes of acetone required for each Selol
concentration would not be cytotoxic themselves. Bl
nanoparticles were prepared using the same method
with the same concentrations of the components used
for SPN but without Selol. Each treatment was per-
formed in triplicate with different Se concentrations
(50, 100 and 150 μg/mL) and times of exposure (24, 48
and 72 h). The concentration of PVM/MA in the treat-
ments with Bl was equivalent to that used in the SPN
treatment.
To verify whether the biological activity of SPN was
maintained during storage at 4°C, the cell viability was also
evaluated on days 1st and 60th after preparation of the SPN.
Cell viability
The cells were seeded and treated as described above.
Next, the cells were incubated with 0.5 mg/mL MTT for
2.5 h. The MTT solution was removed, and formazan
was extracted from the cells with dimethyl sulfoxide
[41]. The absorbance at a wavelength of 595 nm was
measured using a spectrophotometer (Spectramax M2,USA) and was used as an index of cell viability. The re-
sults were expressed as percentages relative to the con-
trol groups after 24 h of treatment.
Cell counting
A549 and normal cells were treated with SPN (100 μg/mL)
for 24, 48 and 72 h. Next, the cells were harvested and
quantified using a Scepter™ Cell Counter (Millipore, USA).
Morphology and confluence of cells
The morphology and confluence of the cells were ana-
lyzed using a phase contrast microscope (Zeiss, Germany)
and the AxioVision® software (Zeiss, Germany). For ultra-
structural analysis, the cells were fixed, contrasted and
dehydrated in agreement with the method described by
Carneiro et al. (2011) [42]. Ultrathin sections were ob-
served through TEM, and the images were digitized.
Real-time cell index
Real-time cell analysis was performed with a RTCA in-
strument (xCelligence, Roche, Switzerland) [43]. Briefly,
A549 cells were seeded for 24 h on plates containing
microelectronic sensor arrays and later incubated with
medium or treated with different concentrations of SPN
(50, 100, and 150 μg/mL). The cells were automatically
monitored every 15 min for up to 100 h. Two independ-
ent experiments were performed.
Reactive oxygen species
The intracellular production of reactive oxygen species
(ROS) was measured using 2’,7’-dichlorodihydrofluorescein
diacetate (DCFH-DA) as an oxidation-sensitive fluo-
rescent probe. The ROS production was evaluated
in A549 and HL60 cells [34,35]. The HL60 cells were
cultured in RPMI (Roswell Park Memorial Institute
medium) supplemented with 10% FBS and 1% antibiotic
solution and were maintained at 37°C, 5% CO2 and 80%
humidity. Then, the cells treated or not treated with
SPN (100 μg/mL) for different times (1, 4, 8, 24, 48
and 72 h) were stained with 2.5 μM DCFH-DA for
30 min at 37°C. HL60 cells treated with 10 mM phorbol
12-myristate 13-acetate (PMA) were used as a positive
control. A total of 10,000 events per sample were ana-
lyzed using a FC500® cytometer (Beckman Coulter,
USA) and the FlowJo 7.6.3 software.
Annexin V-FITC/propidium iodide staining
The externalization of phosphatidylserine and the loss of
plasma membrane integrity, which are signs of apoptosis
and necrosis, respectively, were assessed with a double-
staining kit consisting of FITC-labeled annexin V and pro-
pidium iodide (PI). The cells were incubated with 100 μL
of binding buffer containing 10 mM HEPES/NaOH
(pH 7.4), 140 mM NaCl and 2.5 mM CaCl2. Next, 5 μL of
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and the cells were incubated for 15 min in the dark at RT.
The cells were analyzed with a CyFlow® space cytometer
(Partec, Germany), and 10,000 events were counted per
sample. Cells not incubated with Annexin V-FITC and
PI were used as the negative control. Cells incubated
with 100 μg/mL SS for 24, 48 and 72 h were used as
annexin V staining-positive cells. Cells killed by heating at
60°C for 5 min were used as PI staining-positive cells. All
of the cytometry results reported in the CyFlow® space
were analyzed using the Windows™ Flow Max® and FlowJo
7.6.3 software programs.
DNA fragmentation and cell cycle analysis
The cell cycle was evaluated by the quantification of
total DNA. A549 cells were fixed with 70% ethanol for
2 h at 4°C, rinsed with PBS, incubated with 50 μg/mL
RNase A for 30 min at 37°C and stained with 50 μg/mL
PI for 30 min at RT [44]. A total of 10,000 events per
sample were counted with a CyFlow® cytometer, and the
percentage of cells in different phases of the cell cycle
was determined. Only those cells presenting DNA con-
tent in the range of 2n-4n were considered in the cell
cycle analysis. Fragmented DNA was identified in the
sub-G1 (DNA content < 2n) population and calculated
considering the totality of events.
Mitochondrial membrane potential
The fluorescent cationic substrate rhodamine 123
(Rho123) was used to assess the mitochondrial mem-
brane potential (ΔΨm) in A549 cells. The cells were in-
cubated with 5 μg/mL Rho123 for 15 min at RT and
washed twice with PBS [45]. A total of 10,000 events
were analyzed per sample using a CyFlow® cytometer.
Quantitative RT-PCR (qRT-PCR)
A549 cells were harvested after SPN treatment (100 μg/mL)
for 24, 48 and 72 h. The total RNA was extracted using
a GeneJet RNA purification kit and was then treated
with DNase I, free-RNase kit. cDNA was synthesized
from mRNA using cDNA Maxima reverse transcription
reagents. qRT-PCR was performed using a TaqMan gene
expression assay, and the amplification reactions were
performed using a Fast Real-time System 7900HT (Ap-
plied BioSystems, USA). The following primers (and
their specifications) were used: ACTB (Hs99999903_
m1), BAX (Hs00180269_m1), BCL2 (Hs00608023_m1),
CAT (Hs00156308_m1), CDC25C (Hs00156411_m1), CC
NB1 (Hs01030099_m1), CCND1 (Hs00765553_m1), CCN
E1 (Hs01026536_m1), CYP1A1 (Hs00153120_m1), GAP
DH (Hs02758991_g1), GPX1 (Hs00829989_gH), SIRT3
(Hs00953477_m1), and WEE1 (Hs00268721_m1). All
of the kits were used according to the manufacturer’s
instructions.The cDNA dilutions were defined based on threshold
cycles (CT) (17 – 20) derived from the amplification of
the constitutive gene GAPDH (R2 ≥ 0.9974). Each sample
was normalized based on the mRNA expression level of
GAPDH. The gene expression values were obtained
using the 2-ΔΔCT equation. A gene was considered to be
differentially expressed when the transcript rate (FC, fold
change) was at changed by at least twofold compared
with the untreated control sample [46].
Statistical analysis
All of the experiments were performed in triplicate and
repeated three times. The results are represented as
the means ± standard deviation. Significant differences
were assessed by one- or two-way analyses of variance
followed by Tukey or Bonferroni’s post-tests (α = 0.05)
using the GraphPad Prism 5.0 software.
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